Predicting Outcomes

Artificial Neural Networks and Nomograms
  • Audrey C. Rhee
  • Christopher J. Di Blasio
  • Daniel Cho
  • Michael W. Kattan
Part of the Current Clinical Urology book series (CCU)


In 2002, an estimated 189,000 new cases of prostate cancer were diagnosed, with approx 30,200 deaths related to diseases (1). Thus prostate cancer is the most common cancer and the second most common cause of cancer death in American men. The advent of prostate-specific antigen (PSA) screening has led to a stage migration, whereby most prostate cancers are discovered while the tumor is still confined to the gland proper (2). Treatments for clinically localized tumors include radical prostatectomy (RP) (3–6), external-beam radiotherapy (XRT) (7,8) brachytherapy (9), and conservative management, with or without androgen-deprivation therapy (ADT) (10,11). Although randomized clinical trials are under way to compare treatment options (12), it is uncertain which treatment provides the best outcomes with respect to cancer control, as well as quality of life. The natural history of prostate cancer is generally indolent, requiring many years to elapse between its diagnosis and the development of disease-related symptoms. Therefore, a patient with prostate cancer is more likely to be affected by competing risk factors (i.e., comorbid illness) during his lifetime, and thus there is an obvious need for instruments to aid the patient and his physician in decision making when selecting a therapy for prostate cancer.


Prostate Cancer Radical Prostatec Localize Prostate Cancer Trad Stat Concordance Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2000; 52: 23–47.CrossRefGoogle Scholar
  2. 2.
    Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166: 416–419.PubMedCrossRefGoogle Scholar
  3. 3.
    Ohori M, Wheeler TM, MW K, et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154: 1818–1824.PubMedCrossRefGoogle Scholar
  4. 4.
    Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276: 615–619.PubMedCrossRefGoogle Scholar
  5. 5.
    Trapasso JG, de Kernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 1821–1825.PubMedGoogle Scholar
  6. 6.
    Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395–406.PubMedCrossRefGoogle Scholar
  7. 7.
    Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: long-term results. J Urol 1994; 152: 1781–1785.PubMedGoogle Scholar
  8. 8.
    Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995; 154: 456–459.PubMedCrossRefGoogle Scholar
  9. 9.
    Ragde H, Blasko JC, Grimm PD, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997; 80: 442–453.PubMedCrossRefGoogle Scholar
  10. 10.
    Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242–248.PubMedCrossRefGoogle Scholar
  11. 11.
    Albertsen PC, Fryback DG, Storer BE, et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626–631.PubMedCrossRefGoogle Scholar
  12. 12.
    Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152: 1910–1914.PubMedGoogle Scholar
  13. 13.
    Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001; 165: 1562–1568.PubMedCrossRefGoogle Scholar
  14. 14.
    Ross PL, Gerigk C, Gonen M, et al. Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin Urol Oncol 2002; 20: 82–88.PubMedCrossRefGoogle Scholar
  15. 15.
    Hogarth R. Judgment and Choice: the Psychology of Decision, 2nd ed. John Wiley and Sons, New York, 1987.Google Scholar
  16. 16.
    Kattan M. Expert systems in medicine. In: Smelser NJ, Baltes PB, eds. International Encyclopedia of the Social Behavioral Sciences. Elsevier, New York, 2001.Google Scholar
  17. 17.
    Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361–387.PubMedCrossRefGoogle Scholar
  18. 18.
    Stamey TA, Yemoto CM, McNeal JE. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000; 163: 1155–1160.PubMedCrossRefGoogle Scholar
  19. 19.
    Bauer JJ, Connelly RR, Seterhenn IA, et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 1998; 159: 929–933.PubMedCrossRefGoogle Scholar
  20. 20.
    Calvanese CB, Kahane H, Carlson GD. A presurgical staging of prostate cancer. Infect Urol 1999; 22–28.Google Scholar
  21. 21.
    Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer 2002; 1: 90–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Harrell FE Jr, Margolis PA, Gove S. Development of a clinical prediction model for an ordinary outcome: the World Health Organization multicenter study of clinical signs and etiological agents of pneumonia, sepsis, and meningitis in young infants. WHO/ARI young infant multicenter study group. Stat Med 1998; 17: 909–944.PubMedCrossRefGoogle Scholar
  23. 23.
    Harrell FE Jr, Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3: 143–152.PubMedCrossRefGoogle Scholar
  24. 24.
    Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 876: 835–842.PubMedCrossRefGoogle Scholar
  25. 25.
    Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 200 1; 166: 63–67.Google Scholar
  26. 26.
    Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18: 3352–3359.PubMedGoogle Scholar
  27. 27.
    Kattan M. Statistical prediction models, artificial neural networks, and the sophism “I am a patient, not a statistic”. J Clin Oncol 2002; 20: 885–887.PubMedCrossRefGoogle Scholar
  28. 28.
    D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.PubMedCrossRefGoogle Scholar
  29. 29.
    Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766–771.PubMedCrossRefGoogle Scholar
  30. 30.
    Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499–1507.PubMedGoogle Scholar
  31. 31.
    Begg CB, Cramer ID, Venkatraman FS. Comparing tumour staging and grading systems: a case study and a review of the issues, using thymoma as a model. Stat Med 2000; 19: 1997–2014.PubMedCrossRefGoogle Scholar
  32. 32.
    Cantor SB, Kattan MW. Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making 2000; 20: 468–470.PubMedCrossRefGoogle Scholar
  33. 33.
    Harrell FE, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA 1982; 247: 2543.Google Scholar
  34. 34.
    Snow PB, Smith DS, Catalona WJ. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 1994; 152: 1923–1926.PubMedGoogle Scholar
  35. 35.
    Burk HB, Goodman PH, Rosen DB. Artificial neural networks improve the accuracy of cancer survival prediction. Cancer 1997; 79: 857–862.CrossRefGoogle Scholar
  36. 36.
    Picard RR, Berk KN. Data splitting. American Statistician 1990; 44: 140–147.Google Scholar
  37. 37.
    Efron B. Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Stat Assoc 1983; 78: 316.CrossRefGoogle Scholar
  38. 38.
    Efron B, Tibshirani R. An Introduction to the Bootstrap. Chapman and Hall, New York, 1993.Google Scholar
  39. 39.
    Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am Statistics 1983; 37: 36–48.Google Scholar
  40. 40.
    Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003; 13: 111–116.PubMedCrossRefGoogle Scholar
  41. 41.
    Cross SS, Harrison RF, Kennedy RL. Introduction to neural networks. Lancet 1995; 346: 1075–1079.PubMedCrossRefGoogle Scholar
  42. 42.
    Fausett L. Fundamentals of Neural Networks: Architectures, Algorithms and Applications. Prentice-Hall International, Englewood Cliffs NJ, 1994.Google Scholar
  43. 43.
    Wei JT, Zhang Z, Barnhill SD, et al. Understanding artificial neural networks and exploring their potential applications for the practicing urologist. Urology 1998; 52: 161–172.PubMedCrossRefGoogle Scholar
  44. 44.
    Hinton GE. How neural networks learn from experience. Sci Am 1992; 267: 144–151.PubMedCrossRefGoogle Scholar
  45. 45.
    Agresti A. Categorical Data Analysis. John Wiley and Sons, New York, 1990, pp. 307–310.Google Scholar
  46. 46.
    Venables WN, Ripley BD. Modern Applied Statistics with S-Plus. Springer, New York, 1999, p. 3.Google Scholar
  47. 47.
    Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445–1451.PubMedCrossRefGoogle Scholar
  48. 48.
    Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millenium. Urology 2001; 58: 843–848.PubMedCrossRefGoogle Scholar
  49. 49.
    Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110–114.PubMedGoogle Scholar
  50. 50.
    Blute ML, Bergstralh EJ, Partin AW, et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000; 164: 1591–1595.PubMedCrossRefGoogle Scholar
  51. 51.
    AJCC Cancer Staging Manual, 4th ed. Lippincott-Raven, Philadelphia, 1992.Google Scholar
  52. 52.
    Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20: 791–796.PubMedCrossRefGoogle Scholar
  53. 53.
    D’Amico AV, Whittington R, Malkowicz SB, et al. A multivariate analysis of clinical and pathologic factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131–138.PubMedCrossRefGoogle Scholar
  54. 54.
    Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 2000; 55: 323–327.PubMedCrossRefGoogle Scholar
  55. 55.
    Meehl PE. Causes and effects of my disturbing little book. J Pers Assess 1986; 50: 370–375.PubMedCrossRefGoogle Scholar
  56. 56.
    Halabi S, Small EJ, Kantoff P, et al. A prognostic model for predicting overall survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol, 2003; 21 (7): 1232–1237.PubMedCrossRefGoogle Scholar
  57. 57.
    Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972–3982.PubMedCrossRefGoogle Scholar
  58. 58.
    Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001; 58: 393–399.PubMedCrossRefGoogle Scholar
  59. 59.
    Eastham JA, Kattan MW, Scardino PT. Nomograms as predictive models. Semin Urol Oncol 2002; 20: 108–115.PubMedCrossRefGoogle Scholar
  60. 60.
    Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1982; 160: 2418.Google Scholar
  61. 61.
    Yan Y, Carvalhal GF, Catalona WJ, et al. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000; 88: 1122–1130.PubMedCrossRefGoogle Scholar
  62. 62.
    Graefen M, Karakiewicz PI, Cagiannos I, et al. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 2002; 7: 141–146.PubMedCrossRefGoogle Scholar
  63. 63.
    Graefen M, Karakiewicz PI, Cagiannos I, et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 2002; 20: 951–956.PubMedCrossRefGoogle Scholar
  64. 64.
    Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2000; 20: 3206–3212.CrossRefGoogle Scholar
  65. 65.
    Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528–534.PubMedCrossRefGoogle Scholar
  66. 66.
    Wheeler TM, Dillioglugil O, Kattan MW, et al. Clinical and pathologic significance of the level and extent of capsular invasion in clinical stage T1–2 prostate cancer. Hum Pathol 1998; 29: 856–862.PubMedCrossRefGoogle Scholar
  67. 67.
    Perez CA, Michalski JM, Purdy JA, et al. Three-dimensional conformal radiation therapy (3-D CRT), brachytherapy, and new therapeutic modalities. Rays 2000; 25: 331–343.PubMedGoogle Scholar
  68. 68.
    Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295–300.PubMedCrossRefGoogle Scholar
  69. 69.
    American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37: 1035.Google Scholar
  70. 70.
    Hilaris BS. Brachytherapy in cancer of the prostate: an historical perspective. Semin Surg Oncol 1997; 13: 399–405.PubMedCrossRefGoogle Scholar
  71. 71.
    Zelefsky MJ, Whitmore WF Jr. Long-term results of retropubic permanent 125-iodine implantation of the prostate for clinically localized prostatic cancer. J Urol 1997; 158: 23–29.PubMedCrossRefGoogle Scholar
  72. 72.
    Ragde H, Korb LJ, Elgamal A, et al. Modern prostate brachytherapy: prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Am Cancer Soc 2000; 89: 135–141.Google Scholar
  73. 73.
    Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 47: 1261–1266.PubMedCrossRefGoogle Scholar
  74. 74.
    D’Amico AV, Vogelzang NA. Prostate brachytherapy: increasing demand for the procedure despite the lack of standardized quality assurance and long-term outcome data. Cancer 1999; 86: 1632–1634.PubMedCrossRefGoogle Scholar
  75. 75.
    Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual 5th ed. Lippincott-Raven, Philadelphia, 1997.Google Scholar
  76. 76.
    Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281: 1598–1604.PubMedCrossRefGoogle Scholar
  77. 77.
    Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonographyguided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized low to high Gleason grade prostate carcinoma. Cancer 1998; 83: 989–1001.PubMedCrossRefGoogle Scholar
  78. 78.
    Veltri RW, Chaudhari M, Miller MC, et al. Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic. Clin Chem 2002; 48: 1828–1834.PubMedGoogle Scholar
  79. 79.
    Horninger W, Bartsch G, Snow PB, et al. The problem of cutoff levels in a screened population: appropriateness of informing screenees about their risk of having prostate carcinoma. Cancer 2001; 91: 1667–1672.PubMedCrossRefGoogle Scholar
  80. 80.
    Han M, Snow PB, Brandt JM, et al. Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. Cancer 2001; 91: 1661–1666.PubMedCrossRefGoogle Scholar
  81. 81.
    Ziada AM, Lisle TC, Snow PB, et al. Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. Cancer 2001; 91: 1653–1660.PubMedCrossRefGoogle Scholar
  82. 82.
    Han M, Snow PB, Epstein JI, et al. A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology 2000; 56: 994–999.PubMedCrossRefGoogle Scholar
  83. 83.
    Finne P, Finne R, Auvinen A, et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000; 56: 418–422.PubMedCrossRefGoogle Scholar
  84. 84.
    Potter SR, Miller MC, Mangold LA, et al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 1999; 54: 791–795.PubMedCrossRefGoogle Scholar
  85. 85.
    Murphy GP, Snow PB, Brandt J, et al. Evaluation of prostate cancer patients receiving multiple staging tests including ProstaScint scintiscans. Prostate 2000; 42: 145–149.PubMedCrossRefGoogle Scholar
  86. 86.
    Murphy GP, Snow P, Simmons SJ, et al. Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients. Prostate 2000; 42: 67–72.PubMedCrossRefGoogle Scholar
  87. 87.
    Mattfeld T, Kestler HA, Hautmann R, et al. Prediction of prostatic cancer progression after radical prostatectomy using artificial neural networks: a feasibility study. BJU Int 1999; 84: 316–323.CrossRefGoogle Scholar
  88. 88.
    Ronco AL, Fernandez R. Improving ultrasonographic diagnosis of prostate cancer with neural networks. Ultrasound Med Biol 1999; 25: 729–733.PubMedCrossRefGoogle Scholar
  89. 89.
    Virtanen A, Gomari M, Kranse R, et al. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination and heredity are significant variables. Clin Chem 1999; 45: 987–994.PubMedGoogle Scholar
  90. 90.
    Wei JT, Ashutosh T. Artificial neural networks in urology. Prog Urol 1999; 54: 945–948.Google Scholar
  91. 91.
    Djavan B, Remzi M, Zlotta A, et al. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002; 20: 921–929.PubMedCrossRefGoogle Scholar
  92. 92.
    Schwartzer G, Schumacher M. Artificial neural networks for diagnosis and prognosis in prostate cancer. Semin Urol Oncol 2002; 20: 89–95.CrossRefGoogle Scholar
  93. 93.
    Schwartzer G, Werner V, Schumacher M. On the misuses of artificial neural networks for prognostic and diagnostic classification in oncology. Stat Med 2000; 19: 541–561.CrossRefGoogle Scholar
  94. 94.
    Kattan MW, Eastham JA. Algorithms for PSA recurrence after treatment of localized prostate cancer. Clin Prostate Cancer 2003; 1 (9): 221–226.PubMedCrossRefGoogle Scholar
  95. 95.
    Kattan MW, Stapleton AM, Wheeler TM, et al. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997; 79: 528–537.PubMedCrossRefGoogle Scholar
  96. 96.
    Kattan MW, Beck JR. Artificial neural networks for medical classification decisions. Arch Pathol Lab Med 1995; 119: 672–677.PubMedGoogle Scholar
  97. 97.
    Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 1997; 12: 299–305.PubMedCrossRefGoogle Scholar
  98. 98.
    Stamey T, Barnhill SD, Zhang Z, et al. A neural network (ProstAsureTM) with high sensitivity and specificity for diagnosing prostate cancer in men with a PSA4.0 ng/mL. J Urol 1997; 157 (Suppl): 364.CrossRefGoogle Scholar
  99. 99.
    Babaian RJ, Fritsche HA, Zhang Z, et al. Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report. Urology 1998; 51: 132–136.PubMedCrossRefGoogle Scholar
  100. 100.
    Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 1998; 52: 455–456.PubMedCrossRefGoogle Scholar
  101. 101.
    Eastham JA, May R, Robertson JL, et al. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology 1999; 54: 709–713.PubMedCrossRefGoogle Scholar
  102. 102.
    Narayan P, Gajendran V, Taylor SP, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995; 46: 205–212.PubMedCrossRefGoogle Scholar
  103. 103.
    Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368–374.PubMedCrossRefGoogle Scholar
  104. 104.
    Gilliland FD, Hoffman RM, Hamilton A, et al. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study. J Urol 1999; 162: 1341–1345.PubMedCrossRefGoogle Scholar
  105. 105.
    Pisansky TM, Blute ML, Suman VJ, et al. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys 1996; 36: 585–591.PubMedCrossRefGoogle Scholar
  106. 106.
    Bluestein DL, Bostwick DG, Bergstralh EJ, et al. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994; 151: 1315–1320.PubMedGoogle Scholar
  107. 107.
    D’Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17: 168–172.PubMedGoogle Scholar
  108. 108.
    D’Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of percentage of positive prostate bopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18: 1164–1172.PubMedGoogle Scholar
  109. 109.
    Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517–523.PubMedCrossRefGoogle Scholar
  110. 110.
    Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 1997; 79: 2154–2161.PubMedCrossRefGoogle Scholar
  111. 111.
    D’Amico AV, Whittington R, Malkowicz SB, et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 1998; 160: 2096–2101.PubMedCrossRefGoogle Scholar
  112. 112.
    Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43: 649–689.PubMedCrossRefGoogle Scholar
  113. 113.
    Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–1597.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Audrey C. Rhee
  • Christopher J. Di Blasio
  • Daniel Cho
  • Michael W. Kattan

There are no affiliations available

Personalised recommendations